News Almirall, S.A.

Equities

ALM

ES0157097017

Real-time Estimate Tradegate Other stock markets 04:32:27 2024-04-25 am EDT			5-day change	1st Jan Change
8.343 ^EUR	-0.50%		+1.83%	-1.19%

Mar. 13	Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	MT
Feb. 19	Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	Mar. 13	BU
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall: share price surges after agreement with Novo Nordisk	Feb. 19	CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024	Feb. 19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19	MT
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology	Feb. 19	BU
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19	CI
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business	Feb. 19	BU
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 18	CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	BU
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	CI
Almirall: messenger RNA alliance with Belgium's etherna	Dec. 12	CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	Dec. 12	MT
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology	Dec. 12	BU
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	Dec. 12	CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023.	Dec. 09	CI
Almirall: share price rises, EU green light for eczema treatment	Nov. 17	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Almirall, S.A.

Equities

ALM

ES0157097017

Summary

Filters